Longevity Fundraising: Active VCs & Aging Biotech Playbook

How to raise venture capital for a longevity or aging biotech startup in 2026.

How to Raise Venture Capital for a Longevity Biotech Startup

Longevity biotech — Altos Labs, Retro Biosciences, Life Biosciences, Rejuvenate Bio, BioAge, Loyal (Cellular Longevity), Tally Health, NewLimit, Turn Bio — sits at the intersection of aging science, drug development, and (for consumer plays) regulated biomarker testing.

Why longevity is a distinct fundraising category

Longevity rounds mix mainstream biotech diligence (target biology, IND path, IP position, KOL quality) with aging-specific challenges — the FDA has never approved a drug with 'aging' as an indication, so most programs seek a specific age-related disease indication (fibrosis, sarcopenia, frailty, Alzheimer's, IPF) as the wedge.

The most active longevity VCs

Longevity-dedicated: Kizoo Technology Capital, Longevity Vision Fund, Apollo Health Ventures, Juvenescence, LongeVC, Cambrian BioPharma, Age1 (Laura Deming / early-stage), R42, Healthspan Capital, and Impetus Grants (non-dilutive).

Multi-stage bio-heavy: ARCH Venture Partners (Altos Labs anchor), Flagship Pioneering, Third Rock, Section 32, F-Prime, GV, Foresite Capital, Andreessen Horowitz Bio + Health, and Lux Capital.

Family office / individual: Jeff Bezos (Altos, Unity), Sam Altman (Retro Biosciences, Loyal), Yuri Milner (Altos), Peter Thiel (Unity historically), Larry Ellison, Bryan Johnson (via Blueprint related capital).

Translational science bar

Investors underwrite target validation, in-vivo lifespan/healthspan data in relevant models (mice minimum, ideally dogs for Loyal-style plays), IP position, and IND-enabling toxicology plan. 'Interesting biology' without a translational path does not close Series A.

FDA posture on aging endpoints

The FDA has not approved a therapy for 'aging' as an indication. Fundable paths are (1) specific age-related disease indications (fibrosis, sarcopenia, Alzheimer's, IPF, osteoarthritis), (2) accelerated approval via validated surrogate endpoints, and (3) veterinary market as a first indication (Loyal's approach for canine lifespan).

Consumer longevity considerations

Consumer plays (biomarker testing, supplements, protocols) face different rules — LDT enforcement (post-FDA final rule), FTC advertising scrutiny for anti-aging claims, and payer / reimbursement gaps. Investors weight consumer plays at consumer-CPG multiples, not biotech multiples.

Common mistakes when raising for longevity

Positioning 'aging' as the indication. Vague translational path from mice to humans. Weak IP position on well-known targets (senolytics, NAD boosters). Overreliance on family-office capital without institutional VC validation. Consumer plays claiming biotech multiples.

Frequently asked questions

Which are the most active longevity VCs in 2026?
Kizoo Technology Capital, Longevity Vision Fund, Apollo Health Ventures, Juvenescence, LongeVC, Cambrian BioPharma, Age1, R42, and Healthspan Capital, plus generalist bio-heavy funds ARCH Venture Partners, Flagship Pioneering, Third Rock, Section 32, F-Prime, GV, Foresite Capital, Andreessen Horowitz Bio + Health, and Lux Capital. Significant family-office capital from Jeff Bezos, Sam Altman, Yuri Milner, and Larry Ellison.
Can I pursue 'aging' as an FDA indication?
No. The FDA has not approved a therapy for aging as an indication. Fundable pathways target specific age-related diseases (fibrosis, sarcopenia, Alzheimer's, IPF, osteoarthritis), pursue accelerated approval via validated surrogate endpoints, or start in the veterinary market (Loyal's canine lifespan approach).
What translational data do longevity investors expect?
Target validation, in-vivo mouse lifespan / healthspan data in relevant models, and — for platforms with canine or larger-animal implications — dog or non-human primate data. IND-enabling toxicology plan is expected by Series A.
Do consumer longevity companies get biotech multiples?
No. Biomarker testing, supplements, and consumer protocols are valued at consumer / CPG multiples (typically 2–6x revenue). Positioning consumer plays as biotech usually fails diligence.
How much family-office vs institutional VC is healthy in longevity?
Family-office capital (Bezos, Altman, Milner, Ellison) can lead early rounds, but Series B+ typically requires institutional biotech validation (ARCH, Flagship, Third Rock, Section 32, F-Prime, a16z Bio + Health) for IPO or acquisition optionality.

Related fundraising verticals (40)

Investor directory · Fundraising library · Articles A–Z · Company funding database